228 results on '"Kumada, Hiromitsu"'
Search Results
2. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
3. Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus
4. Favorable Efficacy of Daclatasvir Plus Asunaprevir in Treatment of Elderly Japanese Patients Infected With HCV Genotype 1b Aged 70 and Older
5. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
6. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan
7. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
8. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b
9. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b
10. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C
11. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis
12. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
13. Cover Image, Volume 92, Number 12, December 2020
14. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
15. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
16. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma
17. Determinants of Response to Triple Therapy of Telaprevir, Peginterferon, and Ribavirin in Previous Non-Responders Infected With HCV Genotype 1
18. Amino Acid Substitutions in Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by Antiviral Therapy
19. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy
20. Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma
21. Virus Clearance Reduces Bone Fracture in Postmenopausal Women With Osteoporosis and Chronic Liver Disease Caused by Hepatitis C Virus
22. Influence of Amino-Acid Polymorphism in the Core Protein on Progression of Liver Disease in Patients Infected With Hepatitis C Virus Genotype 1b
23. Losartan Reduces the Onset of Type 2 Diabetes in Hypertensive Japanese Patients With Chronic Hepatitis C
24. Amino Acid Substitutions in the Hepatitis C Virus Core Region of Genotype 1b Are the Important Predictor of Severe Insulin Resistance in Patients Without Cirrhosis and Diabetes Mellitus
25. A Matched Case-Controlled Study of 48 and 72 Weeks of Peginterferon Plus Ribavirin Combination Therapy in Patients Infected With HCV Genotype 1b in Japan: Amino Acid Substitutions in HCV Core Region as Predictor of Sustained Virological Response
26. Efficacy of Low-Dose Intermittent Interferon-Alpha Monotherapy in Patients Infected With Hepatitis C Virus Genotype 1b Who Were Predicted or Failed to Respond to Pegylated Interferon Plus Ribavirin Combination Therapy
27. Substitution of Amino Acid 70 in the Hepatitis C Virus Core Region of Genotype 1b Is an Important Predictor of Elevated Alpha-Fetoprotein in Patients Without Hepatocellular Carcinoma
28. Prolonged-Efficacy of Bisphosphonate in Postmenopausal Women With Osteoporosis and Chronic Liver Disease
29. Successful Treatment of an Entecavir-Resistant Hepatitis B Virus Variant
30. Interferon-Induced Prolonged Biochemical Response Reduces Hepatocarcinogenesis in Hepatitis C Virus Infection
31. Loss of Hepatitis B Surface Antigen From the Serum of Patients With Chronic Hepatitis Treated With Lamivudine
32. Comparison of Interferon and Lamivudine Treatment in Japanese Patients With HBeAg Positive Chronic Hepatitis B
33. Prolonged-Interferon Therapy Reduces Hepatocarcinogenesis in Aged-Patients With Chronic Hepatitis C
34. Response to Long-Term Lamivudine Treatment in Patients Infected With Hepatitis B Virus Genotypes A, B, and C
35. Clinical and Virological Features of Non-Breakthrough and Severe Exacerbation Due to Lamivudine-Resistant Hepatitis B Virus Mutants
36. Persistence of Acute Infection With Hepatitis B Virus Genotype A and Treatment in Japan
37. Hepatocyte Steatosis Is an Important Predictor of Response to Interferon (IFN) Monotherapy in Japanese Patients Infected With HCV Genotype 2a: Virological Features of IFN-Resistant Cases With Hepatocyte Steatosis
38. Favorable Efficacy of Long-Term Lamivudine Therapy in Patients With Chronic Hepatitis B: An 8-Year Follow-Up Study
39. Clinical and Virological Characteristics of Untreated Patients With Chronic Hepatitis C Who Develop Serum Alanine Aminotransferase Flare-up
40. Early Viral Kinetics and Treatment Outcome in Combination of High-Dose Interferon Induction vs. Pegylated Interferon Plus Ribavirin for Naïve Patients Infected With Hepatitis C Virus of Genotype 1b and High Viral Load
41. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens
42. Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance
43. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens
44. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2
45. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b
46. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
47. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens
48. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens.
49. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
50. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.